Digital therapies, also known as DTx, are revolutionising the life sciences sector: they have the potential to close existing gaps in care and open up new business models.
However, certain adjustments are necessary for pharmaceutical companies to be able to utilise these promising opportunities. This is because DTx differ from conventional therapeutics. In addition to the use of appropriate technology and the development of digital expertise, a cultural transformation is also essential. In concrete terms, this means that companies in the life sciences sector need to become much more agile and adapt to continuous innovation.